Theralink Technologies, Inc.
THER · OTC
9/30/2023 | 9/30/2022 | 9/30/2021 | 9/30/2020 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | -0.00 | 0.00 | 0.00 |
| FCF Yield | -10,725.90% | -2,682.30% | -183.13% | -1,500.83% |
| EV / EBITDA | -2.16 | -0.37 | -0.53 | 0.34 |
| Quality | ||||
| ROIC | 75.37% | -2,029.97% | 387.97% | -163.12% |
| Gross Margin | 79.20% | 60.40% | 76.77% | 70.98% |
| Cash Conversion Ratio | 0.19 | 0.42 | 0.87 | 1.09 |
| Growth | ||||
| Revenue 3-Year CAGR | 6.27% | 46.34% | – | – |
| Free Cash Flow Growth | -7.55% | -12.30% | -22.85% | -241.75% |
| Safety | ||||
| Net Debt / EBITDA | -2.15 | -0.35 | -0.03 | 0.43 |
| Interest Coverage | -0.53 | -10.63 | -45.96 | -107.53 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 1.65 | 0.74 |
| Cash Conversion Cycle | -3,539.56 | -1,192.00 | -2,940.04 | -3,758.70 |